Rigel Pharms Drug Patent Portfolio
Rigel Pharms owns 3 orange book drugs protected by 32 US patents Given below is the list of Rigel Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11723905 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | 12 Nov, 2039 | Active |
| US11738018 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | 17 Jul, 2039 | Active |
| US10532047 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | 16 May, 2039 | Active |
| US10959994 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | 16 May, 2039 | Active |
| US11013733 | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) | 16 May, 2039 | Active |
| US11013734 | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation | 16 May, 2039 | Active |
| US11376246 | Inhibiting mutant IDH-1 | 16 May, 2039 | Active |
| US11497743 | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation | 16 May, 2039 | Active |
| US12053463 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | 16 May, 2039 | Active |
| US11273160 | RET inhibitor for use in treating cancer having a RET alteration | 03 Apr, 2039 | Active |
| US11872192 | RET inhibitor for use in treating cancer having a RET alteration | 03 Apr, 2039 | Active |
| US11963958 | RET inhibitor for use in treating cancer having a RET alteration | 03 Apr, 2039 | Active |
| US10030005 | Inhibitors of RET | 01 Nov, 2036 | Active |
| US10414752 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | 18 Sep, 2035 | Active |
| US10550098 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | 18 Sep, 2035 | Active |
| US11498913 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | 18 Sep, 2035 | Active |
| US9834539 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | 18 Sep, 2035 | Active |
| US8771648 | (Trimethoxyphenylamino) pyrimidinyl formulations | 27 Jul, 2032 | Active |
| US8951504 | (trimethoxyphenylamino) pyrimidinyl formulations | 27 Jul, 2032 | Active |
| US7449458 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 04 Sep, 2031 | Active |
| US8263122 | Wet granulation using a water sequestering agent | 24 Nov, 2030 | Active |
| US8652492 | Wet granulation using a water sequestering agent | 06 Nov, 2028 | Active |
| US8163902 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 17 Jun, 2026 | Active |
| US8445485 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 17 Jun, 2026 | Active |
| US8912170 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 17 Jun, 2026 | Active |
| US9283238 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 17 Jun, 2026 | Active |
| US7989448 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 12 Jun, 2026 | Active |
| US7538108 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 28 Mar, 2026 | Active |
| US8211889 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 19 Jan, 2026 | Active |
| US9266912 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 19 Jan, 2026 | Active |
| US9737554 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 19 Jan, 2026 | Active |
| USRE48898 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | 19 Jan, 2026 | Active |
Latest Legal Activities on Rigel Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Rigel Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 May, 2024 | US9283238 |
| Surcharge, Petition to Accept Pymt After Exp, Unintentional. | 07 May, 2024 | US9283238 |
|
Petition to Accept Late Payment of Maintenance Fee Payment Filed
Critical
| 07 May, 2024 | US9283238 |
|
Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted
Critical
| 07 May, 2024 | US9283238 |
|
Petition Decision - Accept Late Payment of Maintenance Fees - Granted
Critical
| 07 May, 2024 | US9283238 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 May, 2024 | US11273160 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 May, 2024 | US11872192 |
|
Email Notification
Critical
| 06 May, 2024 | US11872192 |
|
Email Notification
Critical
| 06 May, 2024 | US11273160 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Apr, 2024 | US10030005 |
|
Email Notification
Critical
| 25 Apr, 2024 | US10030005 |
|
Expire Patent
Critical
| 22 Apr, 2024 | US9283238 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 11 Mar, 2024 | US8263122 |
|
Email Notification
Critical
| 28 Feb, 2024 | US10550098 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Feb, 2024 | US10959994 |
Rigel Pharms Drug Patents' Oppositions Filed in EPO
Rigel Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 07, 2019, by Teva Pharmaceutical Industries, Ltd.. This opposition was filed on patent number EP12759802A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12759802A | Aug, 2019 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
Rigel Pharms's Family Patents
Rigel Pharms drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 34.3% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Rigel Pharms Drug List
Given below is the complete list of Rigel Pharms's drugs and the patents protecting them.
1. Gavreto
Gavreto is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273160 | RET inhibitor for use in treating cancer having a RET alteration |
03 Apr, 2039
(14 years from now)
| Active |
| US11872192 | RET inhibitor for use in treating cancer having a RET alteration |
03 Apr, 2039
(14 years from now)
| Active |
| US11963958 | RET inhibitor for use in treating cancer having a RET alteration |
03 Apr, 2039
(14 years from now)
| Active |
| US10030005 | Inhibitors of RET |
01 Nov, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gavreto's drug page
2. Rezlidhia
Rezlidhia is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11723905 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
12 Nov, 2039
(14 years from now)
| Active |
| US11738018 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
17 Jul, 2039
(14 years from now)
| Active |
| US10532047 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
16 May, 2039
(14 years from now)
| Active |
| US10959994 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
16 May, 2039
(14 years from now)
| Active |
| US11013733 | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
16 May, 2039
(14 years from now)
| Active |
| US11013734 | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
16 May, 2039
(14 years from now)
| Active |
| US11376246 | Inhibiting mutant IDH-1 |
16 May, 2039
(14 years from now)
| Active |
| US11497743 | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
16 May, 2039
(14 years from now)
| Active |
| US12053463 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
16 May, 2039
(14 years from now)
| Active |
| US10414752 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
18 Sep, 2035
(10 years from now)
| Active |
| US10550098 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
18 Sep, 2035
(10 years from now)
| Active |
| US11498913 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
18 Sep, 2035
(10 years from now)
| Active |
| US9834539 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
18 Sep, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezlidhia's drug page
3. Tavalisse
Tavalisse is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8771648 | (Trimethoxyphenylamino) pyrimidinyl formulations |
27 Jul, 2032
(7 years from now)
| Active |
| US8951504 | (trimethoxyphenylamino) pyrimidinyl formulations |
27 Jul, 2032
(7 years from now)
| Active |
| US7449458 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
04 Sep, 2031
(6 years from now)
| Active |
| US8263122 | Wet granulation using a water sequestering agent |
24 Nov, 2030
(6 years from now)
| Active |
| US8652492 | Wet granulation using a water sequestering agent |
06 Nov, 2028
(3 years from now)
| Active |
| US8163902 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
17 Jun, 2026
(1 year, 6 months from now)
| Active |
| US8445485 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
17 Jun, 2026
(1 year, 6 months from now)
| Active |
| US8912170 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
17 Jun, 2026
(1 year, 6 months from now)
| Active |
| US9283238 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
17 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7989448 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
12 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7538108 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
28 Mar, 2026
(1 year, 4 months from now)
| Active |
| US8211889 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
19 Jan, 2026
(1 year, 2 months from now)
| Active |
| US9266912 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
19 Jan, 2026
(1 year, 2 months from now)
| Active |
| US9737554 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
19 Jan, 2026
(1 year, 2 months from now)
| Active |
| USRE48898 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
19 Jan, 2026
(1 year, 2 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tavalisse's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List